CYLD is a deubiquitinating (DUB) enzyme that has a pivotal role in modulating nuclear factor kappa B (NF-κB) signaling pathways by removing the lysine 63-and linear-linked ubiquitin chain from substrates such as tumor necrosis factor receptor-associated factor 2 (TRAF2) and TRAF6. Loss of CYLD activity is associated with tumorigenicity, and levels of CYLD are lost or downregulated in different types of human tumors. In the present study, we found that high CYLD expression was associated with better overall survival and relapse-free neuroblastoma patient outcome, as well as inversely correlated with the stage of neuroblastoma. Retinoic acid-mediated differentiation of neuroblastoma restored CYLD expression and promoted SUMOylation of CYLD. This posttranslational modification inhibited deubiquitinase activity of CYLD against TRAF2 and TRAF6 and facilitated NF-κB signaling. Overexpression of non-SUMOylatable mutant CYLD in neuroblastoma cells reduced retinoic acid-induced NF-κB activation and differentiation of cells, but instead promoted cell death.
INTRODUCTION
Neuroblastoma is the most common extracranial tumor in children, accounting for 15% of childhood cancer deaths. 1, 2 Neuroblastoma originates from the sympathetic nervous system and is composed of undifferentiated and poorly differentiated neuroblasts arising from the different stages of sympathoadrenal lineage of neural crest origin. [2] [3] [4] [5] Earlier reports have identified that in neuroblastoma the expression of markers that are upregulated in later stages of the neuronal lineage of sympathetic nervous system differentiation, such as neurotrophic tyrosine kinase, receptor, type 1 (NTRK1) and growth-associated protein 43 (GAP43), is indicative of better prognosis. 6, 7 The age of patient, genetic aberrations (N-MYC amplification and deletion of chromosome 11 q) and metastatic spread are important factors with regard to treatment decision and patient prognosis. The International Neuroblastoma Staging System is divided into 1-4 stage groups and stage 4 S, which has the ability to spontaneously regress. 3, 8 Patients older than 1½ years with stage 4 disease have the worse prognosis, with an overall survival of o 50%. 2 Surgery, chemotherapy, radiotherapy and high-dose chemotherapy with autologous stem cell transplantation are commonly used as treatment therapy for neuroblastoma patients. In addition, terminal differentiation of neuroblastoma cells induced by retinoids is used as a current standard therapy for high-risk neuroblastomas to eliminate residual tumor cells that are resistant after intensive chemotherapy and stem cell transplantation. 1, [9] [10] [11] Retinoids act on upregulating diverse sets of differentiationrelated gene expression via retinoic acid receptors (RAR and RXR) such as GAP43 and neurotrophin receptors (TrK). [12] [13] [14] In addition, retinoids can also downregulate the expression of certain genes such as N-MYC, concurrent with the arrest of cell proliferation. 11, 5, 16 Elucidating the mechanisms behind the differentiation of neuroblastoma cells is therefore of clinical importance. CYLD mutation was originally discovered in patients developing familial cylindromatosis, which is a benign tumor of skin appendages. 17 Loss of CYLD expression has also been found in many different tumors; 18 however, the function of CYLD in neuroblastoma is unknown. CYLD is a deubiquitinating (DUB) enzyme that cleaves lysine 63 and linear-linked polyubiquitin chains from the substrates. 19, 20 Many of the known DUB substrates for CYLD include components of nuclear factor kappa B (NF-κB) signaling such as tumor necrosis factor receptorassociated factor 2 (TRAF2), tumor necrosis factor receptorassociated factor 6 (TRAF6), NF-κB essential modifier (NEMO, also named IKKγ) and B-cell lymphoma 3, [21] [22] [23] [24] thus affecting the downstream signaling pathway. As many reports highlight the importance of CYLD expression, the regulatory mechanism of CYLD at the protein level and its influence on cellular activity and signaling remains largely unknown.
In the present study, we were able to identify posttranslational modification of CYLD by small ubiquitin-related modifier (SUMO) upon all-trans-retinoic acid (ATRA)-induced neuroblastoma differentiation. This posttranslation modification resulted in reduced deubiquitinase activity of CYLD against its target substrates, including TRAF2 and TRAF6, and modification of NF-κB signaling.
RESULTS

CYLD expression is associated with clinical outcomes in neuroblastoma patients
To investigate whether CYLD expression is altered in neuroblastoma, we studied the association of CYLD levels with neuroblastoma patient outcomes. A Kaplan-Meier survival analysis using a microarray data set from 88 neuroblastoma patients 25 revealed that high CYLD expression was associated with better overall survival ( Figure 1a ) and relapse-free neuroblastoma patient outcomes ( Figure 1b) . Furthermore, the relative expression level of CYLD was inversely correlated with tumor stage using the International Neuroblastoma Staging System (Figure 1c ). Oncogene N-MYC is often amplified in aggressive and undifferentiated neuroblastomas and its expression correlates with advanced disease. [26] [27] [28] Analysis of N-MYC amplification in neuroblastoma patients showed that CYLD expression was significantly lower in N-MYC-amplified compared with N-MYC-non-amplified neuroblastomas (Figure 1d ). We could not find any correlation of CYLD expression with the different cellular phenotypic variants of neuroblastoma cell lines, including neuroblastic (N-type; SK-N-F1, SK-N-RA, SH-SY5Y and IMR-32) or more malignant neuroblastoma cells, the intermediate type (I-type; SK-N-BE(2)C and LA-N-2). Instead, it appeared that cell lines with the lowest expression level of CYLD tend to be either multidrug resistant or derived from a patient after therapy (Figures 1e and f) .
ATRA treatment increases NF-κB activation As we found a negative correlation between CYLD and N-MYC expression (see Figure 1d ), this led us to hypothesize that CYLD expression could be regulated upon differentiation of neuroblastoma. To test this hypothesis, we treated the SK-N-BE(2)C cell line with ATRA. We chose to use the SK-N-BE(2)C cell line, as this cell line expresses low levels of CYLD (see Figures 1e and f) and is highly aggressive and multidrug resistant, but still has the capacity to differentiate into neuron-like cells in response to ATRA treatment. Figures 2a and b show ATRA-mediated cell differentiation evaluated by changes in cell morphology including neurite outgrowth and downregulation of N-MYC in SK-N-BE(2)C cells. This effect was reversible by the removal of ATRA and replacing it with dimethyl sulfoxide (DMSO) (Figure 2a ; ATRA → DMSO). One of the ATRA-mediated signaling pathways is the activation of the transcription factor, NF-κB. [29] [30] [31] Consistent with these reports, the NF-κB repressor protein, inhibitor of NF-κB (IκB-α), level was decreased during ATRA-induced neuroblastoma treatment, and returned to normal levels when ATRA was replaced with DMSO ( Figure 2c ). This observation was supported by NF-κΒ luciferase assay, where an increase in κB promoter activity upon ATRA treatment compared with DMSO-treated cells was observed (Figure 2d ). The ATRA-mediated NF-κB activation was transient, as after 8-10 days, we could see the downregulation of NF-κB promoter activity (Figure 2e ). Prolonged stimulation with ATRA (8-10 days) also led to an increase in cell death (Figure 2f ). These results suggest that short time stimulation with ATRA increases NF-κB signaling and promotes differentiation of cells, whereas prolonged ATRA stimulation reduces NF-κB activation and mediates cell death.
CYLD is SUMOylated upon ATRA treatment Next, we investigated whether stimulation of neuroblastoma cells with ATRA can affect CYLD expression. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analyses showed a significant upregulation of CYLD gene expression in response to ATRA, which was reversible after ATRA removal (Figures 3a and b) . At the protein level, after 3-6 days, we observed a slow-migrating band in cells treated with ATRA, corresponding to a posttranslational modified form of CYLD ( Figure 3b ). This slow-migrating band was lost when the ATRA was removed ( Figure 3c ). As one of the posttranslational modifiers that promotes cellular differentiation is SUMOylation, 32, 33 we studied whether ATRA can alter the overall levels of SUMOylated proteins. An increase in the total levels of SUMO1-and SUMO2/3-modified proteins in cells treated with ATRA was observed. However, this effect was reversible when the medium was replaced from ATRA to DMSO (Figure 3d ). To investigate whether endogenous CYLD is SUMOylated during ATRA-induced neuroblastoma differentiation, Figure 1 . High CYLD expression is associated with better overall survival and is relapse-free in neuroblastoma (a and b) Kaplan-Meier survival curves for overall survival (a) and relapse-free survival (b) from 88 neuroblastoma patients (Versteeg-88-MAS5.0-u133p2) according to CYLD expression level (high or low) using the R2 microarray analysis and visualization platform (http://r2.amc.nl). Most significant expression cutoff value was used and P-value between two groups was calculated using a log-rank test. SUMOylation ( Figure 5g ). To further confirm that the DUB activity of CYLD against its substrates is reduced because of SUMOylation, cells were transfected with TRAF2, full-length or CYLD-K40R and ubiquitin in the presence or absence of SUMO constructs. Figure 5h shows that in the absence of SUMO (lanes 5 and 7), the effect of overexpression of wild-type CYLD and CYLD-K40R on cleavage of the lysine 63-linked ubiquitin of TRAF2 was similar (Figure 5h ). However, expression of SUMO together with wild-type CYLD prevented deubiquitination of TRAF2 to the same levels as in the control (lanes 3 and 4). In contrast, CYLD-K40R unconjugated ubiquitin from TRAF2, both in the presence and absence of SUMO construct (lanes 6 and 7). These results suggest that deubiquitin activation of CYLD is modulated by SUMOylation.
To test the effect of CYLD SUMOylation in ATRA-mediated NF-κB activation, we transfected SK-N-BE(2)C neuroblastoma cells with wild-type and CYLD-K40R and performed NF-κB promoter luciferase activity. CYLD-K40R mutant significantly reduced ATRAinduced κB promoter activity (Figure 5i ), as well as degradation of IκB-α and phosphorylation of p65 ( Figure 5j ). As expected, overexpression of wild-type CYLD and CYLD-K40R reduced NF-κB promoter activity, degradation of IκB-α and phosphorylation of p65 compared with mock-transfected cells in the absence of ATRA treatment (Supplementary Figure S4) . The morphologic effects of the overexpression of CYLD or CYLD-K40R in the presence of ATRA for 1 h were quantified by counting the number of transfected cells with cell processes longer than the length of two cell bodies as an indication of differentiation. In SK-N-BE(2)C cells, overexpression of CYLD induced long processes in 61% of the transfected cells, a substantially higher number than cells expressing EGFP only, where 25% of transfected cells had long processes. Expression of CYLD-K40R resulted in a decreased number of cells with long processes (35%; Figure 5k and Supplementary Figure S5 ). Taken together, these results suggest that SUMOylation of CYLD at lysine 40 interferes with CYLD DUB activity without any alteration in the stability, subcellular translocation or substrate affinity changes. Furthermore, SUMOylation of CYLD in neuroblastoma mediated by ATRA induces NF-κB activation and differentiation via inhibition of CYLD DUB activity (see Figure 5i) .
To investigate whether CYLD expression can be correlated with differentiation markers, we used a data set from 88 neuroblastoma patients and compared CYLD expression with late sympathetic neuronal differentiation and early neural crest-associated genes. As demonstrated in Figure 6 and Table 1 , we found strong correlation between CYLD and late sympathetic neuronal differentiation marker genes, such as NTRK1, GAP43, NPY, STMN2 and B-cell CLL/lymphoma 2 ( Figure 6a and Table 1 ), whereas two of the early neural crest-associated genes, vimentin (VIM) and inhibitor of DNA binding 2 (ID2), were inversely correlated with CYLD expression (Figure 6b and Table 1 ). DISCUSSION Neuroblastoma is a rare childhood cancer that arises from the developing sympathetic nervous system. Many factors including age and stage, as well as the genetic features of the tumor, determine whether it will spontaneously regress or metastasize and become refractory to therapy. There are multiple studies defining the role of different tumor suppressor genes in the development or progression of neuroblastoma. 34 In the present study, we investigated the role of deubiquitination enzyme CYLD in neuroblastomas. Initially, we found that higher CYLD expression in neuroblastoma patient samples correlated with better survival and lower tumor stages. Furthermore, CYLD expression was significantly lower in N-MYC amplified, which are prediction markers for poor outcomes in neuroblastoma. 27 In addition, low CYLD expression was observed in a subset of neuroblastoma cell lines that are multidrug resistant or derived from relapsed neuroblastoma after intensive chemotherapy. Recently, ATRA has been included to the standard of care for high-risk neuroblastoma. 35 Consistent with our findings that N-MYC-nonamplified patients have significantly higher CYLD expression, ATRA rescues the levels of CYLD in neuroblastoma through the gene transcription mechanism. Furthermore, analyzing microarray data from neuroblastoma patient samples showed that CYLD expression was positively correlated with gene expression of late differentiation markers, including STMN2, SCG2, NTRK1, BCL2 and GAP43, while neural crest marker genes, including VIM and ID2, were negatively correlated with CYLD expression. In general, the expression of markers that are expressed in later stages of differentiation is an indication of better prognosis. 11, 17 Previous studies identified SUMO to have a vital role in cell differentiation. Gene encoding proteins involved in SUMOylation are upregulated during Ca 2+ -induced human keratinocyte cell differentiation and in ATRA-induced acute promyelocytic leukemia cell differentiation. 32, 33 In the present study, we found that ATRA treatment of neuroblastoma cell lines leads to a transient increase in the expression of SUMO1 and SUMO2 proteins. In addition, ATRA also promoted a transient activation of the classical NF-κB signaling pathway including IκB-α degradation, phosphorylation of p65 and NF-κB promoter activity. The highest activation of NF-κB signaling and neurite outgrowth, which is a sign of neuroblastoma cell differentiation, could be observed between 1 and 6 days treatment with ATRA. Prolonged stimulation with ATRA (after 6 days) reduced NF-κB signaling and instead facilitated cell death.
ATRA-mediated upregulation of CYLD at the protein level was followed by an immediate posttranslational modification of CYLD through the SUMOylation process. However, this effect was transient. Constant CYLD SUMOylation was observed only between 1 and 6 days, whereas after 8-10 days, as the total level of CYLD protein was unchanged, the SUMOylation of CYLD was reduced. As no changes in protein stability, substrate binding or localization of CYLD SUMO mutant compared with wild-type CYLD could be observed, reduced DUB activity was identified. As transient CYLD SUMOylation paralleled NF-κB activation, we investigated whether this posttranslational modification could interfere with the NF-κB signaling pathway in ATRA-stimulated neuroblastoma cells. Ubiquitination of TRAF2 and/or TRAF6 is an essential process for NF-κB activation, and direct binding and deubiquitination of TRAF2/6 by CYLD attenuates downstream signaling. 36, 37 Here, we could show that SUMOylation of CYLD at lysine 40 prevents removal of the lysine 63-linked polyubiquitin chain from its substrates including TRAF6 and TRAF2. Furthermore, CYLD SUMOylation regulates differentiation T Kobayashi et al inhibition of CYLD deubiquitinase activity was essential for ATRAmediated NF-κB signaling and differentiation of neuroblastoma cells, whereas prolonged ATRA treatment led to reduced CYLD SUMOylation, which, in turn, prevented NF-κB signaling pathway and promoted cell death. This finding suggests that the balance between non-SUMOylated and SUMOylated CYLD can direct differentiation or cell death by regulating NF-κB signaling in neuroblastoma (see Figure 5i) . Indeed, retinoic acid can induce differentiation and apoptosis of neuroblastoma cells. 38, 39 Previously, it has been shown that CYLD promotes apoptosis or necrosis by blocking NF-κB signaling activity. 24, 40, 41 In addition, the NF-κB pathway is generally tightly regulated with a negative feedback loop, for instance, by the induction of SUMO protease SENP2 upon genotoxic stress to attenuate cell survival response. 42 This raises the possibility that SUMOylation of CYLD could be reversed after initiation of neuroblastoma differentiation by negative feedback loop. This is crucial as CYLD is exclusively localized in the cytoplasm, and it has been reported that SUMOylation of extra nuclear protein can have a significant acute effect on neuronal function. 43 In conclusion, our study provides evidence that CYLD expression in neuroblastoma is rescued by ATRA-mediated differentiation of cells and posttranslational modification of CYLD via SUMOylation. The SUMOylation of CYLD interferes with its DUB activity, which is vital for directing cell signaling decisions to promote either differentiation or apoptosis. Figure 6 . Correlation between CYLD and neural crest markers or late differentiation markers. (a) Correlation between CYLD and sympathetic neuronal differentiation marker genes (NTRK1 and GAP43) were analyzed by calculating the Pearson's correlation coefficient using 88 neuroblastoma patients data extracted from the R2 microarray analysis and visualization platform (http://r2.amc.nl). Statistical analysis was carried out using two-sided unpaired t-test. (b) Correlation between CYLD and the early neural crest-associated genes (VIM and ID2) were analyzed by calculating the Pearson's correlation coefficient using 88 neuroblastoma patients data extracted from the R2 microarray analysis and visualization platform (http://r2.amc.nl). Statistical analysis was carried out using two-sided unpaired t-test. Prolonged ATRA treatment leads to reduced CYLD SUMOylation, which, in turn, prevents the activation of NF-κB signaling via deubiquitination of TRAF2/6 and facilitates cell death.
MATERIALS AND METHODS
Cell culture and neuroblastoma differentiation treatments SK-N-BE(2)C and SH-SY5Y human neuroblastoma cells were grown in minimum essential medium (MEM) (Thermo scientific, Vastra Frolunda, Sweden), whereas LA-N-2, SK-N-RA, SK-N-F1 and IMR-32 human neuroblastoma cells were grown in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO, USA). HeLa cells were kept at 37°C in a humidified atmosphere containing 5% CO 2 and 95% air. For induction of neuroblastoma differentiation, SK-N-BE(2)C cells were cultured in MEM with 1% of fetal bovine serum, 100 IU/ml penicillin and 100 μg/μl streptomycin in the presence of 1 or 5 μM ATRA (Sigma-Aldrich) for different time points. Photomicrographs of the cell morphologies were taken with a phasecontrast microscope.
For morphologic studies at the end of transfections, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min and mounted on microscopy slides. The transfected cells were considered to have long processes if the length of the process exceeded that of two cell bodies. At least 200 transfected cells per experiment were counted.
Immunoblotting and immunoprecipitation
For immunoprecipitation studies, cells were washed three times in ice-cold PBS and lysed on ice in a RIPA lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl, pH 7.6, 5 mM EDTA, 0.1% SDS, 1% Na deoxycholate) supplemented with EDTA-free Complete protease inhibitor cocktail (Roche, GmbH, Mannheim, Germany), 2.1 mM Na 3 VO 4 , 0.02 mM lodoacetamide (Sigma-Aldrich), 20 mM N-ethylmaleimide (Sigma-Aldrich) and 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich), and lysates were passaged through a 23 G syringe. Lysates were cleared by centrifugation at 14 000 g for 10 min at 4°C, and the supernatants were precleared two times with immunoglobulin G beads for 60 min before immunoprecipitation. The precleared lysates were incubated overnight with 1-2 μg of antibodies, followed by incubation with protein G-coupled microbeads for 30 min on rotation at 4°C. The immune complexes were recovered by applying the lysates on μColumns placed in the magnetic field of a μMACS separator (Miltenyi Biotec Norden AB, Lund, Sweden). Following washes, the complexes were eluted with sample buffer. For denatured condition, lysates containing 8 M urea was used for lysing cells and the lysates were diluted 20 times with lysis buffer without urea before immunoprecipitation.
For the immunoblotting process, whole-cell lysates were prepared using RIPA buffer with protease inhibitors and were transferred onto the polyvinylidene difluoride membranes after being resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Membranes were preincubated with 5% dried milk in PBS, followed by incubation with primary antibodies. The membranes were incubated with the following antibodies: rabbit polyclonal TRAF2 (C-20; Santa cruz, CA, USA), rabbit polyclonal TRAF6 (H-274; Santa Cruz), rabbit polyclonal hemagglutinin (Y-11; Santa Cruz), rabbit monoclonal phospho-NF-κB p65 (serine 536; Cell Signaling, Beverly, MA, USA; no. 3033), rabbit monoclonal NF-κB p65 (4764; Cell Signaling), rabbit polyclonal His (2365; Cell Signaling), rabbit monoclonal K63 linkage-specific polyubiquitin (D7A11; Cell Signaling), rabbit monoclonal CYLD (D1A10; Cell Signaling), mouse monoclonal SUMO1 (21C7; Invitrogen, Camarillo, CA, USA), rabbit polyclonal SUMO1 (PW9460; Enzo Life Sciences, Farmington, NY, USA), rabbit polyclonal SUMO2/3 (PW9465; Enzo Life Sciences), rabbit polyclonal SUMO2/3 (ab3742; Abcam, Cambridge, UK), mouse monoclonal M2 Flag (F3165; Sigma-Aldrich) and previously generated rabbit polyclonal CYLD. 22 Secondary horseradish peroxidase-conjugated antibodies were obtained from GE Healthcare (Freiburg, Germany) and antibodies conjugated to Alexa dyes from Invitrogen. Control immunoglobulin G were obtained from Abcam and goat serum used for blocking from Sigma-Aldrich. The chemiluminescence was captured with a charge-coupled device camera (Fujifilm, Tokyo, Japan).
qRT-PCR
RNA was isolated using a Perfect Pure RNA Cell and Tissue Kit (5 PRIME, Hilden, Germany) according to the manufacturer's instructions. First-strand cDNA synthesis was performed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster city, CA, USA) with random primers and 1-2 μg of RNA. Reaction for qRT-PCR was prepared using cDNAs with SYBR Green QPCR Master Mix (Agilent, Santa Clara, CA, USA) and qRT-PCR was performed on the Mx3005P Real-Time Thermocycler 
Apoptosis assay
Apoptosis was evaluated, using NucleoCounter NC-3000 (Chemometec, Lillerød, Denmark), in conformity with the DNA fragmentation assay. Concisely, cells were grown on 6-well plates, harvested by trypsinization and the trypsinized cells were pooled with the cells floating in the medium. After a short centrifugation, the supernatant was removed and the precipitated cells were washed once with PBS. After a second centrifugation, the cells were resuspended in a small volume of PBS, and the single-cell suspensions were added to ice-cold 70% ethanol for fixation. Samples were vortexed and stored for 12-24 h at − 20°C. Ethanolsuspended cells were centrifuged and the ethanol carefully decanted. Cells were washed once with PBS and then resuspended with NucleoCounter Solution 3 (1 μg/ml 4′,6-diamidino-2-phenylindole, 0.1% Triton X-100 in PBS), followed by incubation for 5 min at 37°C. Samples of 10 μl volume were loaded into a slide chamber (NC-slide A8), and the DNA fragmentation protocol was used according to the manufacturer's instructions (ChemoMetec).
NF-κB luciferase assay
The luciferase activity in cells transiently transfected with reporter constructs containing the kB promoter was determined using the Dual Luciferase Assay system (Promega, Madison, WI, USA). The luminescent signal was quantitated using the FLUOstar Optima Plate Reader (BMG Labtech, Varmdo, Sweden). Luciferase expression was measured in cells transfected with plasmid constructs carrying the firefly luciferase reporter gene. As an internal control, plasmid pGL4.73 (Promega), containing the Renilla luciferase reporter gene, was co-transfected. The transfections were performed in Opti-MEM media containing 15 μl of Polyfect Transfection Reagent (Qiagen, Valencia, CA, USA), and the cells were assayed for luciferase activity at 24 h posttransfection, using reporter plasmids.
Immunofluorescence and confocal microscopy Cells were washed in PBS, fixed with 4% paraformaldehyde in PBS for 4 min, washed two times in PBS and thereafter permeabilized and blocked with 5% goat serum or 5% bovine serum albumin and 0.3% Triton X-100 in PBS for 30 min. Cells were incubated with primary antibodies for 1 h. Following washes in PBS, cells were incubated with secondary Alexa Fluor 546-conjugated antibodies in PBS for 1 h, followed by extensive washes in PBS and mounting on object slides using 20 μl PVA-DABCO (9.6% polyvinyl alcohol, 24% glycerol and 2.5% 1,4-diazabicyclo[2.2.2]octane in 67 mM Tris-HCl, pH 8.0). The images were obtained using a Zeiss LSM710 confocal microscope (Zeiss, Jena, Germany).
In vitro SUMOylation assay
One microgram of 6His-tagged CYLD purchased from Ubiquigent (Dundee, UK) was used as a substrate for in vitro SUMOylation assay using a SUMOylation Kit (Enzo Life Sciences) according to the manufacturer's instructions. Negative control reaction was carried out in the absence of ATP. After incubating the reaction for 1 h at 30°C, the reaction was stopped by adding 2x sample buffer. SUMOylation of the protein was detected by immunoblotting using the anti-SUMO1 and anti-SUMO2/3 antibodies (Enzo Life Sciences).
In vitro deubiquitination assay
For in vitro deubiquitination assay, sumoylated and non-sumoylated CYLD were obtained by immunoprecipitation using the lysate prepared from SK-N-BE(2)C cells co-transfected with Flag, Flag-CYLD or Flag-CYLD-K40R together with His-SUMO1. The immunoprecipitates were incubated with 200 ng/μl of poly-K63-ubiquitin in a reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA pH 8.0 and 2 mM dithiothreitol) in a total volume of 30 μl. The reactions were incubated for 2.5 h at 37°C and the reaction was terminated by adding SDS sample buffer including dithiothreitol. The reaction products were run on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel followed by immunoblotting.
Pull-down assay
For the pull-down assay, HeLa cells were grown in 6-well plates in the presence of 10% serum, containing DMEM-GlutaMAXTM-1. After reaching 80% confluence, the cells were transfected with 2 μg of expression plasmids for 24 h. The cells were lysed with buffer containing 50 mM TrisHCl, 150 mM NaCl, 0.5 mM EDTA and protease inhibitors. Equal amounts of cell lysate were used for the immunoprecipitation of Flag, using antiFlag M2 affinity gel (Sigma-Aldrich), TRAF2 (C-20; Santa Cruz), TRAF6 (H-274; Santa Cruz), hemagglutinin (Y-11; Santa Cruz), SUMO1 (PW9460; Enzo Life Sciences) or SUMO2/3 (ab3742, Abcam) antibodies and incubated overnight at 4°C. The samples were centrifuged for 5 s at 10 000 g, and the supernatants were discarded. The pellets were washed three times with lysis buffer and the protein concentration was measured in the resulting supernatants. Equal amounts of protein and Ni-NTA magnetic agarose beads (Qiagen) for His pull-down, Flag-peptide for Flag pull-down or protein A/G for pulling down antibodies were added to the mixture, incubated for 2 h at 4°C and centrifuged for 5 s at 10 000 g. The bead complexes were collected and denatured for 5 min at 100°C, followed by 2 min centrifugation at 12 000 g. The supernatants were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes.
Statistical analyses
Statistical analyses were performed using GraphPad Prism5 Software (GraphPad Software, San Diego, CA, USA). Results are expressed as mean ± s.e.m., or as percent. P-values o 0.05 were deemed statistically significant. Comparisons between groups were made using the MannWhitney U-test. A correlation analysis was performed by determining the Pearson's product-moment correlation coefficient.
